MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Valeant Pharmaceuticals Intl Company Profile (NYSE:VRX)

Consensus Ratings for Valeant Pharmaceuticals Intl (NYSE:VRX) (?)
Ratings Breakdown: 4 Sell Rating(s), 15 Hold Rating(s), 10 Buy Rating(s)
Consensus Rating:Hold (Score: 2.21)
Consensus Price Target: $72.94 (289.43% upside)

Analysts' Ratings History for Valeant Pharmaceuticals Intl (NYSE:VRX)
Show:
DateFirmActionRatingPrice TargetActions
6/27/2016RBC CapitalReiterated RatingSector PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/22/2016JPMorgan Chase & Co.Reiterated RatingOverweight -> Hold$50.00 -> $35.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/20/2016Wells FargoReiterated RatingSellView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/9/2016BTIG ResearchReiterated RatingNeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/8/2016GuggenheimReiterated RatingBuy$55.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/8/2016BMO Capital MarketsReiterated RatingHold$44.00 -> $38.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/8/2016Jefferies GroupReiterated RatingBuy$53.00 -> $40.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/8/2016Stifel NicolausLower Price TargetBuy$65.00 -> $55.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/7/2016MizuhoReiterated RatingSell$18.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/7/2016BarclaysReiterated RatingHold$34.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/7/2016Piper JaffrayReiterated RatingSellView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/3/2016Canaccord GenuityReiterated RatingHold$40.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/1/2016Morgan StanleyReiterated RatingHold$39.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/29/2016SusquehannaReiterated RatingHold$105.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/29/2016S&P Equity ResearchReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/3/2016Rodman & RenshawLower Price TargetBuy$105.00 -> $102.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/1/2016Citigroup Inc.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/22/2016NomuraReiterated RatingNeutral$60.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/16/2016TD SecuritiesReiterated RatingHold$110.00 -> $45.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/16/2016ScotiabankDowngradeOutperform -> Sector Perform$42.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/15/2016CIBCDowngradeSector Perform -> Sector Underperform$90.00 -> $24.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/2/2016Deutsche BankReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/21/2015Bank of AmericaReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/23/2015Maxim GroupReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/2/2015Goldman SachsDowngradeBuy -> Neutral$180.00 -> $122.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/23/2015OppenheimerReiterated RatingMarket PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/19/2015Evercore ISIReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/20/2015JMP SecuritiesBoost Price TargetMarket Outperform$48.00 -> $50.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/10/2015Howard WeilInitiated CoverageOutperform$290.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/30/2015Cantor FitzgeraldBoost Price TargetBuy$222.00 -> $271.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/25/2015CRT CapitalBoost Price TargetBuy$180.00 -> $220.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/20/2014AegisReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/8/2014ING GroupUpgradeBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/27/2014 forward)
Earnings History for Valeant Pharmaceuticals Intl (NYSE:VRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
6/7/2016Q116$1.37$1.27$2.34 billion$2.37 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/15/2016Q415$2.61$2.50$2.75 billion$2.80 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/19/2015Q315$2.68$2.74$2.06 billion$2.79 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/23/2015Q215$2.46$2.58$2.04 million$2.73 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/29/2015Q115$2.34$2.36$1.89 billion$2.20 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/24/2015Q414$2.56$2.58$2.23 billion$2.28 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/20/2014Q314$1.99$2.11$2.06 billion$2.06 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/31/2014Q214$1.91$1.91$1.06 billion$1.99 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2014Q114$1.72$1.76$1.04 billion$1.85 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/27/2014Q413$2.06$2.15$986.30 million$2.06 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/31/2013Q313$1.40$1.51$884.14 million$1.54 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2013Q213$1.28$1.34$820.09 million$1.10 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/2/2013Q113$1.25$1.30$1.04 billion$1.07 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/28/2013Q412$1.21$1.34$654.17 million$946.67 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/2/2012Q312$1.13$1.15$875.91 million$884.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/2/2012$0.99$1.01ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/3/2012$0.96$0.99ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/3/2011$0.57$0.66ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/4/2011$0.65$0.73ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/9/2011$0.51$0.56ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/24/2011$0.45$0.51ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Valeant Pharmaceuticals Intl (NYSE:VRX)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20161$1.60$1.60$1.60
Q3 20161$1.83$1.83$1.83
Q4 20161$2.10$2.10$2.10
(Data provided by Zacks Investment Research)
Dividend History for Valeant Pharmaceuticals Intl (NYSE:VRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Valeant Pharmaceuticals Intl (NYSE:VRX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/10/2016Joseph C PapaCEOBuy202,000$24.48$4,944,960.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/21/2015Ronald Harold FarmerDirectorBuy1,500$181.60$272,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/31/2015Robert L RosielloCFOBuy7,875$254.28$2,002,455.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/12/2015Robert L RosielloEVPBuy12,900$232.51$2,999,379.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/9/2015Ronald Harold FarmerDirectorBuy1,000$260.63$260,630.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/8/2015Ronald Harold FarmerDirectorBuy500$289.20$144,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/2/2015Pavel MirovskyEVPSell38,000$238.01$9,044,380.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/26/2015Anne Clem WhitakerDirectorBuy7,500$234.67$1,760,025.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/4/2015Robert Roswell Chai-OnnEVPSell90,938$222.54$20,237,342.52View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/10/2014Jeffrey W UbbenInsiderBuy250,000$140.06$35,015,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/3/2014Katharine Berghuis StevensonDirectorBuy1,500$145.73$218,595.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/24/2014Jeffrey W UbbenInsiderBuy210,000$142.25$29,872,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/23/2014Robert Roswell Chai-OnnEVPSell10,203$121.70$1,241,705.10View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/13/2014Robert Roswell Chai-OnnEVPSell10,000$130.08$1,300,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2014Norma Ann ProvencioDirectorSell5,000$132.18$660,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/21/2014Laizer KornwasserEVPBuy2,481$134.97$334,860.57View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/3/2014Norma Ann ProvencioDirectorSell5,000$136.23$681,150.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/24/2014Laizer KornwasserEVPBuy2,536$132.15$335,132.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/13/2014Norma Ann ProvencioDirectorSell5,000$133.00$665,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/14/2013J. Michael PearsonCEOBuy184,247$81.41$14,999,548.27View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/18/2013Laizer KornwasserEVPBuy3,500$107.38$375,830.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/6/2013Ronald Harold FarmerDirectorBuy1,500$107.98$161,970.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/13/2013Laizer KornwasserEVPBuy1,000$99.02$99,020.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/6/2013Norma Ann ProvencioDirectorSell4,000$100.25$401,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/3/2013Norma Ann ProvencioDirectorSell5,000$99.68$498,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/29/2013Fred HassanDirectorBuy51,000$99.01$5,049,510.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/28/2013Ronald Harold FarmerDirectorBuy2,500$102.36$255,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/23/2013Robert Roswell Chai-OnnEVPBuy5,032$99.30$499,677.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/12/2013Brian StolzEVPBuy4,500$100.71$453,195.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/9/2013Laizer KornwasserEVPBuy3,500$100.36$351,260.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/19/2013G Mason MorfitInsiderBuy1,352,941$85.00$114,999,985.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/12/2013Lloyd Mitchell SegalDirectorBuy3,190$84.16$268,470.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/11/2013Norma Ann ProvencioDirectorSell6,000$85.26$511,560.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/11/2013Laizer KornwasserEVPBuy2,000$70.61$141,220.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/7/2012Brian M StolzEVPBuy2,040$52.76$107,630.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/6/2012Howard Bradley SchillerCFOBuy18,300$54.10$990,030.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Valeant Pharmaceuticals Intl (NYSE:VRX)
DateHeadline
06/27/16 06:04 AMNext Weeks Broker Price Targets For Valeant Pharmaceuticals International, Inc. (NYSE:VRX) - Fiscal Standard
06/27/16 06:04 AMValeant Pharmaceuticals Intl Inc (NYSE:VRX) Hot News Update: 24 June 2016 - Money News (press release)
06/27/16 04:00 AMBears Are Back as Valeant Shorts Surge Most Since April: Chart -
06/25/16 06:25 PMJP Morgan disclosed (NYSE:VRX) Valeant Pharmaceuticals, lowering its target price to $35 earlier today
06/25/16 10:49 AMJP Morgan Gives Valeant Pharmaceuticals Price Target With Potential 61.74% Upside
06/25/16 10:49 AMPrice Target Update on Valeant Pharmaceuticals International (NYSE:VRX)
06/24/16 07:10 PMMorgan Stanley lowers Valeant Pharmaceuticals Intl Inc (NYSE:VRX) Estimates; Here's Why
06/24/16 09:47 AMValeant Pharmaceuticals, (NYSE:VRX), WisdomTree Investments, (NASDAQ:WETF)
06/24/16 09:22 AMVRX Stock: Valeant Pharmaceuticals Intl Inc Needs to Create Value, NOT Sell off Assets - <p><a rel="nofollow" href="http://investorplace.com">InvestorPlace</a><a rel="nofollow" href="http://investorplace.com">InvestorPlace - Stock Market News, Stock Advice & Trading Tips</a></p> <p>Valeant can afford its debt without sacrificing assets, and VRX stock holders should expect value creation over a short-term solution.</p> <p>The post <a rel="nofollow" href="http://investorplace.com/2016/06/retaining-assets-best-valeant-vrx-stock/">VRX Stock: Valeant Pharmaceuticals Intl Inc Needs to Create Value, NOT Sell off Assets</a> appeared first on <a rel="nofollow" href="http://investorplace.com">InvestorPlace</a>.</p>
06/23/16 07:58 PMHC Stocks Buzzer: Valeant Pharmaceuticals Intl Inc (NYSE:VRX), Emergent Biosolutions Inc (NYSE:EBS) - share market updates (press release)
06/23/16 07:58 PMAnalysts Change Price Targets on Apple Inc. (AAPL) and Valeant Pharmaceuticals Intl Inc (VRX); Here's Why - Smarter Analyst
06/23/16 09:43 AMAnalysts watching two Stocks: Valeant Pharmaceuticals International, Inc. (NYSE:VRX) , Johnson & Johnson (NYSE:JNJ) - Street Updates
06/23/16 09:43 AMPhillipe Laffont's Latest Investment Moves: Valeant Pharmaceuticals Intl Inc (VRX) and Facebook Inc (FB) - Smarter Analyst
06/23/16 09:28 AMForget a 'Flash Crash'; How About a 'Flash Squeeze' Instead? -
06/23/16 09:06 AMValeant Pharmaceuticals (VRX) Stock Rating Downgraded at JPMorgan -
06/22/16 07:04 PMValeant Pharmaceuticals Intl Inc (NYSE:VRX) Witnesses Major Management Transition - TCC
06/22/16 06:16 AMValeant Pharmaceuticals Intl Inc (VRX) Option Buyers Go Bargain Hunting - Schaeffers Research (blog)
06/22/16 06:07 AMCFO Moves: Taro Pharmaceutical, Valeant -
06/22/16 03:04 AMWhat Do Analysts Think about Valeant? -
06/21/16 06:37 PMVALEANT PHARMACEUTICALS INTERNATIONAL, INC. : Change in Directors or Principal Officers (form 8-K)
06/21/16 06:37 PMValeant Pharmaceuticals Intl Inc (VRX) Use of Non-GAAP Financials Could Be More Problematic: Analyst
06/21/16 06:37 PMValeant Pharmaceuticals Intl Inc (VRX) Option Buyers Go Bargain Hunting
06/21/16 06:37 PMRSI Alert: Valeant Pharmaceuticals International (VRX) Now Oversold
06/21/16 05:55 AMOption Bulls Cheer the Valeant Pharmaceuticals Intl Inc (VRX) Bounce - Schaeffers Research (blog)
06/21/16 05:55 AMValeant Pharmaceuticals Intl Inc's (VRX) Subsidiary Bausch + Lomb Launches PreserVision AREDS 2 Formula + ... - SSL
06/20/16 08:31 AMBulls and Bear in Spotlight- Valeant Pharmaceuticals International (NYSE:VRX), Veracyte (NASDAQ:VCYT), Hologic ... - Seneca Globe
06/20/16 08:31 AMActive Stocks on Frontline- Valeant Pharmaceuticals International (NYSE:VRX), Ariad Pharmaceuticals (NASDAQ:ARIA ... - Seneca Globe
06/20/16 08:31 AMValeant: Rebound To $29 Possible - Seeking Alpha
06/20/16 08:31 AMValeant Pharmaceuticals Intl Inc (NYSE:VRX) Hot News Update – 17 June 2016 - Money News (press release)
06/19/16 06:04 AMValeant Pharmaceuticals International Inc Guides for Strong Prescriptions Growth: RBC Capital - TCC
06/19/16 04:08 AM[$$] Deutsche aims to raise ?1bn from socially responsible products - [at Financial Times] - Deutsche Bank has partnered with an ethical investment specialist to launch a series of investment products in anticipation of a surge in demand for socially responsible investments from European clients. ...
06/18/16 06:16 AMValeant Pharmaceuticals International, Inc. (NYSE:VRX) Ratings Reaffirmed At RBC Capital - TCC
06/18/16 06:16 AMValeant Pharmaceuticals International, Inc. (NYSE:VRX) Invests $27.5 Million in Canada - TCC
06/17/16 06:53 PMValeant Pharmaceuticals Intl Inc (VRX) Invests $27.5 Million in Canada
06/17/16 09:51 AMBright Trending Healthcare Stocks: Valeant Pharmaceuticals Intl Inc (NYSE:VRX), Great Basin Scientific Inc (NASDAQ ... - Money News (press release)
06/17/16 09:51 AMValeant Pharmaceuticals Intl Inc (VRX) Announces Significant Investments In Canadian Operations - Smarter Analyst
06/17/16 09:01 AMIs Valeant Stock a Safe Short? -
06/16/16 08:49 AMValeant Pharmaceuticals Intl Inc (NYSE:VRX) strong product pipeline ignored by bears – Guggenheim
06/16/16 08:49 AMValeant Pharmaceuticals Announces Launch Of New PreserVision® AREDS 2 Formula + Multivitamin
06/14/16 06:46 PMAnalyst's Valuable Buzzers: Valeant Pharmaceuticals International, Inc. (NYSE:VRX) , Sarepta Therapeutics, Inc ... - Street Updates
06/14/16 06:46 PMNoticeable Healthcare Stocks News Recap: Valeant Pharmaceuticals Intl Inc (NYSE:VRX), Great Basin Scientific Inc ... - Money News (press release)
06/14/16 06:46 PMValeant Pharmaceuticals Intl Inc (VRX) Stock Drops on Sale of Dermatology Assets - Bidness ETC
06/14/16 05:04 PMEdward Jones' Fehr: Valeant Still a Wait-and-See Story -
06/14/16 05:37 AMNotable Analysts Ratings: Valeant Pharmaceuticals International, Inc. (NYSE:VRX) , Sarepta Therapeutics, Inc ... - Street Updates
06/14/16 05:37 AMBill Ackman's Increasing Stake in Valeant Pharmaceuticals Intl Inc (VRX) - Smarter Analyst
06/13/16 12:41 PMValeant CEO Joe Papa Trades ~$5 Million Of Shares - Benzinga - BenzingaValeant CEO Joe Papa Trades ~$5 Million Of SharesBenzingaValeant Pharmaceuticals Intl Inc VRX CEO Joseph Papa bought 202,000 shares at $24.48 per share Monday morning. The purchase came after key events last week. Tuesday: Reported Q1 Adj. EPS $1.27 vs $1.37 Est., Sales $2.4B vs $2.38B Est. Tuesday: ...and more »
06/13/16 10:07 AMValeant Pharmaceuticals Intl Inc (VRX) Pops on CEO Stock Purchase - Schaeffers Research (blog)
06/13/16 09:42 AMValeant Pharmaceuticals International, Inc. :VRX-CA: Earnings Analysis: Q1, 2016 By the Numbers : June 13, 2016 -
06/13/16 09:22 AMValeant Climbs After CEO Buys $4.9M In Shares -
06/13/16 09:11 AMValeant shares rise after big CEO stock purchase -
About Valeant Pharmaceuticals Intl

Valeant Pharmaceuticals Intl logoValeant Pharmaceuticals International, Inc. is a specialty pharmaceutical and medical device company. The Company is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries. The Company operates through two segments: developed markets and emerging markets. The Company's developed markets segment consists of sales in the United States of pharmaceutical products, OTC products, and medical device products. The Company's Emerging Markets segment consists of branded generic pharmaceutical products and branded pharmaceuticals, OTC products, and medical device products.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Drug Delivery
  • Sub-Industry: N/A
  • Exchange: NYSE
  • Symbol: VRX
  • CUSIP:
Key Metrics:
  • Previous Close: $18.73
  • 50 Day Moving Average: $25.81
  • 200 Day Moving Average: $58.14
  • P/E Ratio: N/A
  • P/E Growth: 0.40
  • Market Cap: $6.42B
  • Current Quarter EPS Consensus Estimate: $6.64 EPS
Additional Links:
Valeant Pharmaceuticals Intl (NYSE:VRX) Chart for Monday, June, 27, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha